Overview

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Status:
Terminated
Trial end date:
2004-03-18
Target enrollment:
Participant gender:
Summary
Current therapies for Stage III or Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage III or Stage IV Prostate Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage III or Stage IV Prostate Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Burzynski Research Institute